Researchers at Vaxart Inc. and the Center for Vaccine Development at the University of Maryland School of Medicine evaluated ...

Stars have been everywhere this week. In California, Demi Lovato visits Disneyland while Gal Gadot attends her Hollywood Walk ...

Vaxart (VXRT) announced that complete data from the Phase 1b trial of its first-generation oral pill norovirus vaccine candidate in elderly ...

A new orally administered norovirus vaccine tablet has demonstrated promising safety and immunogenicity in older adults.

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 ...

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...

Affected individuals have significantly elevated levels of fatty acid-binding protein 2 ... review board of Columbia University Medical Center. Levels of serum IgG, IgA and IgM endotoxin-core ...

After treatment, the serum IgA and IgG levels in the model group were 1.12 ± 0.37 ... The effect of Astragaloside IV on immune function of regulatory T cell mediated by high mobility group box 1 ...